Tippabhotla, 1,220 patient molnupiravir early treatment RCT: 46% lower hospitalization [p=0.26], 46% better improvement [p<0.0001], and 59% improved viral clearance [p<0.0001] https://c19p.org/tippabhotla
copied to clipboard
Efficacy and Safety of Molnupiravir for the Treatment of Non-Hospitalized Adults With Mild COVID-19: A Randomized, Open-Label, Parallel-Group Phase 3 Trial
et al., SSRN Electronic Journal, doi:10.2139/ssrn.4042673
RCT 1,220 patients in India, showing lower risk of hospitalization and improved recovery with treatment. CTRI/2021/07/034588.Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom].
|
risk of hospitalization, 46.2% lower, RR 0.54, p = 0.26, treatment 7 of 610 (1.1%), control 13 of 610 (2.1%), NNT 102, day 28.
|
|
risk of no improvement, 46.4% lower, RR 0.54, p < 0.001, treatment 67 of 610 (11.0%), control 125 of 610 (20.5%), NNT 11, day 14.
|
|
risk of no improvement, 52.3% lower, RR 0.48, p < 0.001, treatment 199 of 610 (32.6%), control 417 of 610 (68.4%), NNT 2.8, day 10.
|
|
risk of no improvement, 24.8% lower, RR 0.75, p < 0.001, treatment 433 of 610 (71.0%), control 576 of 610 (94.4%), NNT 4.3, day 5.
|
|
risk of no viral clearance, 59.2% lower, RR 0.41, p < 0.001, treatment 42 of 610 (6.9%), control 103 of 610 (16.9%), NNT 10.0, day 14.
|
|
risk of no viral clearance, 81.0% lower, RR 0.19, p < 0.001, treatment 62 of 610 (10.2%), control 327 of 610 (53.6%), NNT 2.3, day 10.
|
|
risk of no viral clearance, 77.6% lower, RR 0.22, p < 0.001, treatment 113 of 610 (18.5%), control 505 of 610 (82.8%), NNT 1.6, day 5.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Tippabhotla et al., 2/24/2022, Randomized Controlled Trial, India, South Asia, peer-reviewed, 5 authors, study period 1 July, 2021 - 24 August, 2021, average treatment delay 3.0 days.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.